Downregulation of AdipoR1 is Associated with Increased Circulating Adiponectin Levels in Serbian Chronic Kidney Disease Patients

Journal of Medical Biochemistry

Volumn 35, Issue 4, 2016, Pages 436-442

  Sopić, Miron ^a   Joksić, Jelena ^a   Spasojević Kalimanovska, Vesna ^a   Bogavac Stanojević, Nataša ^a   Simić Ogrizović, Sanja ^b,c   Kravljača, Milica ^b   Ivanović, Zorana Jelić ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

adiponectin; AdipoR1; AdipoR2; chronic kidney disease

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR; ADIPONECTIN RECEPTOR 1; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; TRIACYLGLYCEROL; UREA;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HUMAN; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SERBIAN (CITIZEN); SIGNAL TRANSDUCTION;

EID: 84994810293     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.1515/jomb-2016-0007     Document Type: Article

References (29)

1. Ye R, Scherer PE. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol Metab 2013; 2: 133-41.
2. Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab 2013; 17: 185-96.
3. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011; 17: 55-63.
4. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004; 323: 630-5.
5. Lovren F, Pan Y, Quan A, Szmitko PE, Singh KK, Shukla PC, et al. Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. Am J Physiol Heart Circ Physiol 2010; 299: 656-63.
6. Rutkowski JM, Wang ZV, Park AS, Zhang J, Zhang D, Hu MC, et al. Adiponectin promotes functional recovery after podocyte ablation. J Am Soc Nephrol 2013; 24: 268-82.
7. Tulubus F, Mete R, Oznur M, Topcu B. The role of adipo cytokines in colon cancer and adenomas. J Med Biochem 2014; 33; 135-42.
8. El-Shafey EM, Shalan M. Plasma adiponectin levels for prediction of cardiovascular risk among hemodialysis patients. Ther Apher Dial 2014; 18: 185-92.
9. Zoccali C. Cardiovascular risk in uraemic patients: is it fully explained by classical risk factors? Nephrol Dial Transplant 2000; 15: 454-7.
10. Zoccali C, Mallamaci F, Panuccio V, Tripepi G, Cutrupi S, Parlongo S, et al. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int Suppl 2003; 84: 98-102.
11. Cvetković T, Veličković-Radovanović R, Stojanović D, Stefanović N, Ignjatović A, Stojanović I, Sladojević N, Pavlović D. Oxidative and nitrosative stress in stable renal transplant recipients with respect to the immunosuppression protocol - differences or similarities? J Med Biochem 2015; 34: 295-303.
12. Isobe T, Saitoh S, Takagi S, Takeuchi H, Chiba Y, Katoh N, et al. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol 2005; 153: 91-8.
13. Chudek J, Adamczak M, Karkoszka H, Budziński G, Ignacy W, Funahashi T, et al. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 2003; 35: 2186-9.
14. Halberg N, Schraw TD, Wang ZW, Kim JY, Yi J, Hamilton MP, et al. Systematic fate of the adipocyte-derived factor adiponectin. Diabetes 2009; 58: 1961-70.
15. Iwashima Y, Horio T, Kumada M, Suzuki Y, Kihara S, Rakugi H, et al. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol 2006; 98: 1603-8.
16. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with endstage renal disease. J Am Soc Nephrol 2002; 13: 134-41.
17. Novaković I, Maksimović N, Pavlović A, Žarković M, Rovčanin B, Mirković D, Pekmezović T, Cvetković D. Introduction to molecular genetic diagnostics. J Med Biochem 2014; 33: 3-7.
18. Jia T, Carrero JJ, Lindholm B, Stenvinkel P. The complex role of adiponectin in chronic kidney disease. Biochimie 2012; 94: 2150-6.
19. Martinez-Cantarin PM, Waldman S, Doria C, Frank AM, Maley WR, Ramirez CB, et al. The adipose tissue production of adiponectin is increased in end stage renal disease. Kidney Int 2013; 83: 487-94.
20. Marchlewska A, Stenvinkel P, Lindholm B, Danielsson A, Pecoits-Filho R, Lönnqvist F, et al. Reduced gene expression of adiponectin in fat tissue from patients with endstage renal disease. Kidney Int 2004; 66: 46-50.
21. Cui XB, Wang C, Li L, Fan D, Zhou Y, Wu D, et al. Insulin decreases myocardial adiponectin receptor 1 expression via PI3K/Akt and FoxO1 pathway. Cardiovasc Res 2012; 93: 69-78.
22. Springer J, Anker SD, Doehner W. Adiponectin Resistance in Heart Failure and the Emerging Pattern of Metabolic Failure in Chronic Heart Failure. Circ Heart Fail 2010; 3: 181-2.
23. Sopić M, Joksić J, Spasojević-Kalimanovska V, Kalimanovska-Oštrić D, Andelković K, Jelić-Ivanović Z. Are decreased AdipoR1 mRNA levels associated with adiponectin resistance in coronary artery disease patients? Clin Exp Pharmacol Physiol 2015; doi: 10.1111/1440-1681.12361.
24. Shen YY, Charlesworth JA, Kelly JJ, Loi KW, Peake PW. Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol Dial Transplant 2007; 22: 171-8.
25. Tsigalou C, Chalikias G, Kantartzi K, Tziakas D, Kampouromiti D, Vargemezis V, et al. Differential Effect of Base-line Adiponectin on All-Cause Mortality in Hemodialysis Patients Depending on Initial Body Mass Index. Long-Term Follow-Up Data of 4.5 Years. Journal of Renal Nutrition 2012; 23: 45-56.
26. Jorsal A, Tarnow T, Frystyk J, Lajer M, Flyvbjerg A, Parving HH, et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 2008; 74: 649-54.
27. Stenvinkel P. Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. J Ren Nutr 2011; 21: 82-6.
28. Vekic J, Zeljkovic A, Bogavac-Stanojevic N, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Simic-Ogrizovic S, et al. Cox proportional hazard model analysis of survival in end-stage renal disease patients with small-sized highdensity lipoprotein particles. Clinical Biochemistry 2011; 44: 635-41.
29. Zeljkovic A, Vekic J, Spasojevic-Kalimanovska V, Jelic-Ivanovic Z, Bogavac-Stanojevic N, Gulan B, et al. LDL and HDL subclasses in acute ischemic stroke: prediction of risk and short-term mortality. Atherosclerosis 2010; 210: 548-55.